Table of Contents 1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview 1.1 Product Overview and Scope of Chemotherapy Induced Peripheral Neuropathy Treatment 1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type 1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 Calcium Channel α2-delta Ligands 1.2.3 Antidepressants 1.2.4 Opioids 1.2.5 Others 1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application 1.3.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application: 2020 VS 2026 1.3.2 Platinum Agents 1.3.3 Taxanes 1.3.4 Vinca Alkaloids 1.3.5 Others 1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Estimates and Forecasts 1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2015-2026 1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2015-2026 1.4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2020 Versus 2026 2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competition by Manufacturers 2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2015-2020) 2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2015-2020) 2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites, Area Served, Product Type 2.5 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends 2.5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Chemotherapy Induced Peripheral Neuropathy Treatment Players (Opinion Leaders) 3 Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region 3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country 3.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country 3.4.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Region 3.5.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region 3.5.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country 3.6.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.6.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country 3.7.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.7.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Analysis by Type 4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020) 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2015-2020) 4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Market Share by Type (2015-2020) 4.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Analysis by Application 5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020) 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2015-2020) 5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2015-2020) 6 Company Profiles and Key Figures in Chemotherapy Induced Peripheral Neuropathy Treatment Business 6.1 Aptinyx Inc 6.1.1 Corporation Information 6.1.2 Aptinyx Inc Description, Business Overview and Total Revenue 6.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Aptinyx Inc Products Offered 6.1.5 Aptinyx Inc Recent Development 6.2 Asahi Kasei Pharma Corp 6.2.1 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.2.2 Asahi Kasei Pharma Corp Description, Business Overview and Total Revenue 6.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Asahi Kasei Pharma Corp Products Offered 6.2.5 Asahi Kasei Pharma Corp Recent Development 6.3 Regenacy Pharmaceuticals 6.3.1 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.3.2 Regenacy Pharmaceuticals Description, Business Overview and Total Revenue 6.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Regenacy Pharmaceuticals Products Offered 6.3.5 Regenacy Pharmaceuticals Recent Development 6.4 MAKScientific LLC 6.4.1 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.4.2 MAKScientific LLC Description, Business Overview and Total Revenue 6.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.4.4 MAKScientific LLC Products Offered 6.4.5 MAKScientific LLC Recent Development 6.5 Metys Pharmaceuticals AG 6.5.1 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.5.2 Metys Pharmaceuticals AG Description, Business Overview and Total Revenue 6.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Metys Pharmaceuticals AG Products Offered 6.5.5 Metys Pharmaceuticals AG Recent Development 6.6 Nemus Bioscience Inc 6.6.1 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.6.2 Nemus Bioscience Inc Description, Business Overview and Total Revenue 6.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Nemus Bioscience Inc Products Offered 6.6.5 Nemus Bioscience Inc Recent Development 6.7 PledPharma 6.6.1 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.6.2 PledPharma Description, Business Overview and Total Revenue 6.6.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.4.4 PledPharma Products Offered 6.7.5 PledPharma Recent Development 6.8 Sova Pharmaceuticals Inc 6.8.1 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.8.2 Sova Pharmaceuticals Inc Description, Business Overview and Total Revenue 6.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Sova Pharmaceuticals Inc Products Offered 6.8.5 Sova Pharmaceuticals Inc Recent Development 6.9 DermaXon LLC 6.9.1 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.9.2 DermaXon LLC Description, Business Overview and Total Revenue 6.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.9.4 DermaXon LLC Products Offered 6.9.5 DermaXon LLC Recent Development 6.10 Immune Pharmaceuticals Inc 6.10.1 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.10.2 Immune Pharmaceuticals Inc Description, Business Overview and Total Revenue 6.10.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.10.4 Immune Pharmaceuticals Inc Products Offered 6.10.5 Immune Pharmaceuticals Inc Recent Development 6.11 Kineta Inc 6.11.1 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.11.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Description, Business Overview and Total Revenue 6.11.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.11.4 Kineta Inc Products Offered 6.11.5 Kineta Inc Recent Development 6.12 Krenitsky Pharmaceuticals Inc 6.12.1 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.12.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Description, Business Overview and Total Revenue 6.12.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.12.4 Krenitsky Pharmaceuticals Inc Products Offered 6.12.5 Krenitsky Pharmaceuticals Inc Recent Development 6.13 PeriphaGen 6.13.1 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.13.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Description, Business Overview and Total Revenue 6.13.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.13.4 PeriphaGen Products Offered 6.13.5 PeriphaGen Recent Development 6.14 Apexian Pharma 6.14.1 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.14.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Description, Business Overview and Total Revenue 6.14.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.14.4 Apexian Pharma Products Offered 6.14.5 Apexian Pharma Recent Development 6.15 WinSanTor 6.15.1 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.15.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Description, Business Overview and Total Revenue 6.15.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.15.4 WinSanTor Products Offered 6.15.5 WinSanTor Recent Development 6.16 Solasia Pharma K.K. 6.16.1 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served 6.16.2 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Description, Business Overview and Total Revenue 6.16.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020) 6.16.4 Solasia Pharma K.K. Products Offered 6.16.5 Solasia Pharma K.K. Recent Development 7 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis 7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment 7.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List 8.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porter's Five Forces Analysis 10 Global Market Forecast 10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2021-2026) 10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2021-2026) 10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Chemotherapy Induced Peripheral Neuropathy Treatment by Region (2021-2026) 10.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2021-2026) 10.5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2021-2026) 10.6 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2021-2026) 10.7 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2021-2026) 10.8 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate Comparison by Type (2015-2026) Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Comparison by Application: 2020 VS 2026 Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (K Units) (US$ Million) (2020 VS 2026) Table 4. Global Key Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Covered in This Study Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Manufacturers (2015-2020) Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers (2015-2020) Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Unit) of Key Manufacturers (2015-2020) Table 10. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Sales Sites and Area Served Table 11. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Types Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2019) Table 14.Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Chemotherapy Induced Peripheral Neuropathy Treatment Players Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Region (2015-2020) Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2015-2020) Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) by Region (2015-2020) Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2015-2020) Table 20. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2015-2020) (K Units) Table 21. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2015-2020) Table 22. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2015-2020) (US$ Million) Table 23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2015-2020) Table 24. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2015-2020) (K Units) Table 25. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2015-2020) Table 26. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2015-2020) (K Units) Table 29. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2015-2020) Table 32. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2015-2020) (K Units) Table 33. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2015-2020) Table 34. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2015-2020) (K Units) Table 37. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2015-2020) Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020) Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2015-2020) Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) by Type (2015-2020) Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2015-2020) Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Unit) by Type (2015-2020) Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020) Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020) Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2015-2020) Table 48. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 49. Aptinyx Inc Description and Business Overview Table 50. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 51. Aptinyx Inc Main Product Table 52. Aptinyx Inc Recent Development Table 53. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 54. Asahi Kasei Pharma Corp Corporation Information Table 55. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 56. Asahi Kasei Pharma Corp Main Product Table 57. Asahi Kasei Pharma Corp Recent Development Table 58. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 59. Regenacy Pharmaceuticals Corporation Information Table 60. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 61. Regenacy Pharmaceuticals Main Product Table 62. Regenacy Pharmaceuticals Recent Development Table 63. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 64. MAKScientific LLC Corporation Information Table 65. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 66. MAKScientific LLC Main Product Table 67. MAKScientific LLC Recent Development Table 68. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 69. Metys Pharmaceuticals AG Corporation Information Table 70. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 71. Metys Pharmaceuticals AG Main Product Table 72. Metys Pharmaceuticals AG Recent Development Table 73. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 74. Nemus Bioscience Inc Corporation Information Table 75. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 76. Nemus Bioscience Inc Main Product Table 77. Nemus Bioscience Inc Recent Development Table 78. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 79. PledPharma Corporation Information Table 80. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 81. PledPharma Main Product Table 82. PledPharma Recent Development Table 83. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 84. Sova Pharmaceuticals Inc Corporation Information Table 85. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 86. Sova Pharmaceuticals Inc Main Product Table 87. Sova Pharmaceuticals Inc Recent Development Table 88. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 89. DermaXon LLC Corporation Information Table 90. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 91. DermaXon LLC Main Product Table 92. DermaXon LLC Recent Development Table 93. Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 94. Immune Pharmaceuticals Inc Corporation Information Table 95. Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 96. Immune Pharmaceuticals Inc Main Product Table 97. Immune Pharmaceuticals Inc Recent Development Table 98. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 99. Kineta Inc Corporation Information Table 100. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 101. Kineta Inc Main Product Table 102. Kineta Inc Recent Development Table 103. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 104. Krenitsky Pharmaceuticals Inc Corporation Information Table 105. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 106. Krenitsky Pharmaceuticals Inc Main Product Table 107. Krenitsky Pharmaceuticals Inc Recent Development Table 108. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 109. PeriphaGen Corporation Information Table 110. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 111. PeriphaGen Main Product Table 112. PeriphaGen Recent Development Table 113. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 114. Apexian Pharma Corporation Information Table 115. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 116. Apexian Pharma Main Product Table 117. Apexian Pharma Recent Development Table 118. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 119. WinSanTor Corporation Information Table 120. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 121. WinSanTor Main Product Table 122. WinSanTor Recent Development Table 123. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information Table 124. Solasia Pharma K.K. Corporation Information Table 125. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 126. Solasia Pharma K.K. Main Product Table 127. Solasia Pharma K.K. Recent Development Table 128. Sales Base and Market Concentration Rate of Raw Material Table 129. Key Suppliers of Raw Materials Table 130. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List Table 131. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List Table 132. Market Key Trends Table 133. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 134. Key Challenges Table 135. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Type (2021-2026) Table 136. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2021-2026) Table 137. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) Forecast by Type (2021-2026) Table 138. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 139. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Application (2021-2026) Table 140. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) Forecast by Application (2021-2026) Table 141. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Region (2021-2026) Table 142. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2021-2026) Table 143. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2021-2026) (US$ Million) Table 144. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Region (2021-2026) Table 145. Research Programs/Design for This Report Table 146. Key Data Information from Secondary Sources Table 147. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Chemotherapy Induced Peripheral Neuropathy Treatment Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type: 2020 VS 2026 Figure 3. Calcium Channel α2-delta Ligands Product Picture Figure 4. Antidepressants Product Picture Figure 5. Opioids Product Picture Figure 6. Others Product Picture Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Application: 2020 VS 2026 Figure 8. Platinum Agents Figure 9. Taxanes Figure 10. Vinca Alkaloids Figure 11. Others Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2015-2026 (US$ Million) Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Capacity (K Units) (2015-2026) Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Market Share by Region: 2020 Versus 2026 Figure 15. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers in 2020 Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers in 2019 Figure 17. The Global 5 and 10 Largest Players: Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2019 Figure 18. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2015-2020) Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2019 Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2015-2020) Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in 2019 Figure 23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2019 Figure 24. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2019 Figure 25. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 26. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 27. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 28. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 29. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2019 Figure 30. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2019 Figure 31. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 32. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 33. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 34. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 35. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 36. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 37. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 38. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 39. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 40. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 41. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2019 Figure 42. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in 2019 Figure 43. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 44. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 45. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 46. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 47. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 48. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 49. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 50. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 51. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 52. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 53. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 54. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 55. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 56. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 57. Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 58. Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 59. Malaysia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 60. Malaysia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 61. Philippines Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 62. Philippines Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 63. Vietnam Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 64. Vietnam Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 65. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2019 Figure 66. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2019 Figure 67. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 68. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 69. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 70. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 71. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 72. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 73. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2019 Figure 74. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country in 2019 Figure 75. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 76. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 77. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 78. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 79. U.A.E Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2020) (K Units) Figure 80. U.A.E Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (2015-2020) (US$ Million) Figure 81. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2015-2020) Figure 82. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2019 Figure 83. Revenue Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2015-2020) Figure 84. Revenue Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2019 Figure 85. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth by Type (2015-2020) (K Units) Figure 86. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020) Figure 87. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2019 Figure 88. Global Revenue Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2015-2020) Figure 89. Global Revenue Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2020 Figure 90. Aptinyx Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 91. Asahi Kasei Pharma Corp Total Revenue (US$ Million): 2019 Compared with 2018 Figure 92. Regenacy Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 93. MAKScientific LLC Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Metys Pharmaceuticals AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. Nemus Bioscience Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. PledPharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. Sova Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 98. DermaXon LLC Total Revenue (US$ Million): 2019 Compared with 2018 Figure 99. Immune Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 100. Kineta Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 101. Krenitsky Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 102. PeriphaGen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 103. Apexian Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 104. WinSanTor Total Revenue (US$ Million): 2019 Compared with 2018 Figure 105. Solasia Pharma K.K. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 106. Price Trend of Key Raw Materials Figure 107. Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment Figure 108. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Figure 109. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis Figure 110. Channels of Distribution Figure 111. Distributors Profiles Figure 112. Porter's Five Forces Analysis Figure 113. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 114. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 115. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 116. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 117. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 118. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 119. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 120. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 121. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 122. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 123. Bottom-up and Top-down Approaches for This Report Figure 124. Data Triangulation Figure 125. Key Executives Interviewed

Aptinyx Inc Asahi Kasei Pharma Corp Regenacy Pharmaceuticals MAKScientific LLC Metys Pharmaceuticals AG Nemus Bioscience Inc PledPharma Sova Pharmaceuticals Inc DermaXon LLC Immune Pharmaceuticals Inc Kineta Inc Krenitsky Pharmaceuticals Inc PeriphaGen Apexian Pharma WinSanTor Solasia Pharma K.K.